National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa.
SAMRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Cell Rep Med. 2022 Feb 10;3(3):100535. doi: 10.1016/j.xcrm.2022.100535. eCollection 2022 Mar 15.
The Janssen (Johnson & Johnson) Ad26.COV2.S non-replicating viral vector vaccine has been widely deployed for COVID-19 vaccination programs in resource-limited settings. Here we confirm that neutralizing and binding antibody responses to Ad26.COV2.S vaccination are stable for 6 months post-vaccination, when tested against multiple SARS-CoV-2 variants. Secondly, using longitudinal samples from individuals who experienced clinically mild breakthrough infections 4 to 5 months after vaccination, we show dramatically boosted binding antibodies, Fc effector function, and neutralization. These high titer responses are of similar magnitude to humoral immune responses measured in convalescent donors who had been hospitalized with severe illness, and are cross-reactive against diverse SARS-CoV-2 variants, including the neutralization-resistant Omicron (B.1.1.529) variant that currently dominates global infections, as well as SARS-CoV-1. These data have implications for population immunity in areas where the Ad26.COV2.S vaccine has been widely deployed, but where ongoing infections continue to occur at high levels.
杨森（强生）公司的 Ad26.COV2.S 非复制型病毒载体疫苗已广泛应用于资源有限环境下的 COVID-19 疫苗接种计划。在此，我们确认，在针对多种 SARS-CoV-2 变体进行检测时，Ad26.COV2.S 疫苗接种后的 6 个月内，其对中和抗体和结合抗体的应答是稳定的。其次，利用接种后 4 至 5 个月经历临床轻度突破性感染的个体的纵向样本，我们发现结合抗体、Fc 效应功能和中和作用显著增强。这些高滴度的应答与在因重症住院的恢复期供体中测量的体液免疫应答相似，并且对多种 SARS-CoV-2 变体具有交叉反应性，包括目前主导全球感染的中和耐药性奥密克戎（B.1.1.529）变体，以及 SARS-CoV-1。这些数据对于 Ad26.COV2.S 疫苗广泛应用的地区的人群免疫力具有重要意义，因为这些地区的持续感染仍在以较高水平发生。
